Illumina launched Connected Multiomics, a cloud‑based software platform that integrates sequencing, AI analytics and workflows to accelerate multiomic studies for customers, positioning the company to expand into end‑to‑end data services. The release targets labs seeking scalable, integrated analysis across transcriptomics, proteomics and other omic layers. Separately, St. Jude researchers published CHANGE‑seq‑BE in Nature Biotechnology, an unbiased, sensitive method to map base‑editor off‑target activity genome‑wide. Authors said the method has already supported an emergency FDA application by confirming high on‑target specificity for a clinical base‑editing intervention, spotlighting a new safety tool for gene‑editing therapeutics.